Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 439Osteosarcoma 134Sarcoma, Ewing 90Melanoma 81Rhabdomyosarcoma 78Neoplasms 71Gastrointestinal Stromal Tumors 63Neuroblastoma 62Bone Neoplasms 62Colorectal Neoplasms 61Breast Neoplasms 61Ovarian Neoplasms 60Glioblastoma 55Neoplasm Metastasis 52Liposarcoma 52Dendritic Cell Sarcoma, Interdigitating 45Carcinoma, Non-Small-Cell Lung 44Leiomyosarcoma 43Gliosarcoma 42Stomach Neoplasms 41Pancreatic Neoplasms 41Lymphoma 37Uterine Cervical Neoplasms 35Sarcoma, Synovial 35Glioma 35Carcinoma, Renal Cell 35Rhabdoid Tumor 34Neurofibrosarcoma 34Lung Neoplasms 34Sarcoma, Kaposi 33

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal undifferentiated carcinoma × Sarcoma × 1 year × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡